Literature DB >> 18593735

Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later.

Rr Griffiths1, Wa Richards, Mw Johnson, Ud McCann, R Jesse.   

Abstract

Psilocybin has been used for centuries for religious purposes; however, little is known scientifically about its long-term effects. We previously reported the effects of a double-blind study evaluating the psychological effects of a high psilocybin dose. This report presents the 14-month follow-up and examines the relationship of the follow-up results to data obtained at screening and on drug session days. Participants were 36 hallucinogen-naïve adults reporting regular participation in religious/ spiritual activities. Oral psilocybin (30 mg/70 kg) was administered on one of two or three sessions, with methylphenidate (40 mg/70 kg) administered on the other session(s). During sessions, volunteers were encouraged to close their eyes and direct their attention inward. At the 14-month follow-up, 58% and 67%, respectively, of volunteers rated the psilocybin-occasioned experience as being among the five most personally meaningful and among the five most spiritually significant experiences of their lives; 64% indicated that the experience increased well-being or life satisfaction; 58% met criteria for having had a 'complete' mystical experience. Correlation and regression analyses indicated a central role of the mystical experience assessed on the session day in the high ratings of personal meaning and spiritual significance at follow-up. Of the measures of personality, affect, quality of life and spirituality assessed across the study, only a scale measuring mystical experience showed a difference from screening. When administered under supportive conditions, psilocybin occasioned experiences similar to spontaneously occurring mystical experiences that, at 14-month follow-up, were considered by volunteers to be among the most personally meaningful and spiritually significant of their lives.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18593735      PMCID: PMC3050654          DOI: 10.1177/0269881108094300

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  27 in total

1.  Criterion validity of a new measure of self-actualization.

Authors:  G Leclerc; R Lefrançois; M Dubé; R Hébert; P Gaulin
Journal:  Psychol Rep       Date:  1999-12

2.  Comparison of the reactions induced by psilocybin and LSD-25 in man.

Authors:  H ISBELL
Journal:  Psychopharmacologia       Date:  1959

3.  De profundis: spiritual transformations in Alcoholics Anonymous.

Authors:  Alyssa A Forcehimes
Journal:  J Clin Psychol       Date:  2004-05

4.  Quantum change: ten years later.

Authors:  Janet C'de Baca; Paula Wilbourne
Journal:  J Clin Psychol       Date:  2004-05

Review 5.  Human hallucinogen research: guidelines for safety.

Authors:  Mw Johnson; Wa Richards; Rr Griffiths
Journal:  J Psychopharmacol       Date:  2008-07-01       Impact factor: 4.153

6.  Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance.

Authors:  R R Griffiths; W A Richards; U McCann; R Jesse
Journal:  Psychopharmacology (Berl)       Date:  2006-07-07       Impact factor: 4.530

7.  Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.

Authors:  Olivia L Carter; John D Pettigrew; Felix Hasler; Guy M Wallis; Guang B Liu; Daniel Hell; Franz X Vollenweider
Journal:  Neuropsychopharmacology       Date:  2005-06       Impact factor: 7.853

8.  Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.

Authors:  Olivia L Carter; Felix Hasler; John D Pettigrew; Guy M Wallis; Guang B Liu; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2007-09-14       Impact factor: 4.530

Review 9.  Hallucinogens.

Authors:  David E Nichols
Journal:  Pharmacol Ther       Date:  2004-02       Impact factor: 12.310

10.  Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.

Authors:  Felix Hasler; Ulrike Grimberg; Marco A Benz; Theo Huber; Franz X Vollenweider
Journal:  Psychopharmacology (Berl)       Date:  2003-11-13       Impact factor: 4.530

View more
  145 in total

1.  Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness.

Authors:  Katherine A MacLean; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2011-09-28       Impact factor: 4.153

2.  Validation of the revised Mystical Experience Questionnaire in experimental sessions with psilocybin.

Authors:  Frederick S Barrett; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2015-10-06       Impact factor: 4.153

3.  Psilocybin-induced spiritual experiences and insightfulness are associated with synchronization of neuronal oscillations.

Authors:  Michael Kometer; Thomas Pokorny; Erich Seifritz; Franz X Volleinweider
Journal:  Psychopharmacology (Berl)       Date:  2015-08-01       Impact factor: 4.530

4.  LSD enhances the emotional response to music.

Authors:  M Kaelen; F S Barrett; L Roseman; R Lorenz; N Family; M Bolstridge; H V Curran; A Feilding; D J Nutt; R L Carhart-Harris
Journal:  Psychopharmacology (Berl)       Date:  2015-08-11       Impact factor: 4.530

5.  Neurotheology-Matters of the Mind or Matters that Mind?

Authors:  Samarth Shukla; Sourya Acharya; Devendra Rajput
Journal:  J Clin Diagn Res       Date:  2013-05-08

Review 6.  Antidepressive, anxiolytic, and antiaddictive effects of ayahuasca, psilocybin and lysergic acid diethylamide (LSD): a systematic review of clinical trials published in the last 25 years.

Authors:  Rafael G Dos Santos; Flávia L Osório; José Alexandre S Crippa; Jordi Riba; Antônio W Zuardi; Jaime E C Hallak
Journal:  Ther Adv Psychopharmacol       Date:  2016-03-18

7.  A sub-set of psychoactive effects may be critical to the behavioral impact of ketamine on cocaine use disorder: Results from a randomized, controlled laboratory study.

Authors:  E Dakwar; E V Nunes; C L Hart; M C Hu; R W Foltin; F R Levin
Journal:  Neuropharmacology       Date:  2018-01-05       Impact factor: 5.250

8.  Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences.

Authors:  Theresa M Carbonaro; Matthew P Bradstreet; Frederick S Barrett; Katherine A MacLean; Robert Jesse; Matthew W Johnson; Roland R Griffiths
Journal:  J Psychopharmacol       Date:  2016-08-30       Impact factor: 4.153

9.  Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety.

Authors:  Alan K Davis; Frederick S Barrett; Roland R Griffiths
Journal:  J Contextual Behav Sci       Date:  2019-11-16

10.  Interaction of psychoactive tryptamines with biogenic amine transporters and serotonin receptor subtypes.

Authors:  Bruce E Blough; Antonio Landavazo; Ann M Decker; John S Partilla; Michael H Baumann; Richard B Rothman
Journal:  Psychopharmacology (Berl)       Date:  2014-05-07       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.